Empirical Finance’s Adaptimmune Therapeutics ADAP Stock Holding History

Empirical Finance’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800,000	Closed	-$20.8K	–	484
2025 Q4	$20.8K	Hold	800,000	–	–	﹤0.01%	481
2025 Q3	$104K	Hold	800,000	–	–	0.01%	502
2025 Q2	$192K	Buy	+800,000	New	+$214K	0.01%	504

Other funds holding ADAP

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Empirical Finance's ADAP Position: Q1 2026 in Review

Empirical Finance sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 800,000 shares — an estimated $20.8K sold.

Empirical Finance first reported a position in ADAP in Q2 2025 and held it in 3 quarters. The position peaked at $192K in Q2 2025. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.

Empirical Finance reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
Empirical Finance sold 800,000 Adaptimmune Therapeutics shares in Q1 2026, an estimated $20.8K.
Empirical Finance first reported a position in Adaptimmune Therapeutics in Q2 2025 and held it in 3 quarters.
Empirical Finance's Adaptimmune Therapeutics position peaked at $192K in Q2 2025.
1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.

Based on Empirical Finance's 13F filing for Q1 2026, filed 14 May 2026.